Literature DB >> 31664345

Multiple sclerosis has a distinct lipid signature in plasma and cerebrospinal fluid.

Enedina Maria Lobato de Oliveira1, Daniela Antunes Montani2, Diogo Oliveira-Silva3, André Filipe Rodrigues-Oliveira3, Sandro Luiz de Andrade Matas1, Gustavo Bruniera Peres Fernandes4, Ismael Dale Cotrim Guerreiro da Silva5, Edson Guimarães Lo Turco2.   

Abstract

OBJECTIVE: The diagnosis of multiple sclerosis (MS) has changed over the last decade, but remains a composite of clinical assessment and magnetic resonance imaging to prove dissemination of lesions in time and space. The intrathecal synthesis of immunoglobulin may be a nonspecific marker and there are no plasma biomarkers that are useful in the diagnosis of MS, presenting additional challenges to their early detection.
METHODS: We performed a preliminary untargeted qualitative lipidomics mass spectrometry analysis, comparing cerebrospinal fluid (CSF) and plasma samples from patients with MS, other inflammatory neurological diseases and idiopathic intracranial hypertension.
RESULTS: Lipid identification revealed that fatty acids and sphingolipids were the most abundant classes of lipids in the CSF and that glycerolipids and fatty acids were the main class of lipids in the plasma of patients with MS. The area under the curve was 0.995 (0.912-1) and 0.78 (0.583-0.917), respectively. The permutation test indicated that this ion combination was useful for distinguishing MS from other inflammatory diseases (p < 0.001 and 0.055, respectively).
CONCLUSION: This study concluded that the CSF and plasma from patients with MS bear a unique lipid signature that can be useful as a diagnostic biomarker.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31664345     DOI: 10.1590/0004-282X20190122

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  5 in total

Review 1.  Fatty acids role in multiple sclerosis as "metabokines".

Authors:  Haojun Yu; Shuwei Bai; Yong Hao; Yangtai Guan
Journal:  J Neuroinflammation       Date:  2022-06-17       Impact factor: 9.587

2.  Metabolomics of Cerebrospinal Fluid in Multiple Sclerosis Compared With Healthy Controls: A Pilot Study.

Authors:  Michal Židó; David Kačer; Karel Valeš; Zuzana Svobodová; Denisa Zimová; Ivana Štětkárová
Journal:  Front Neurol       Date:  2022-05-26       Impact factor: 4.086

Review 3.  Contribution of Metabolomics to Multiple Sclerosis Diagnosis, Prognosis and Treatment.

Authors:  Marianna Gabriella Rispoli; Silvia Valentinuzzi; Giovanna De Luca; Piero Del Boccio; Luca Federici; Maria Di Ioia; Anna Digiovanni; Eleonora Agata Grasso; Valeria Pozzilli; Alessandro Villani; Antonio Maria Chiarelli; Marco Onofrj; Richard G Wise; Damiana Pieragostino; Valentina Tomassini
Journal:  Int J Mol Sci       Date:  2021-10-15       Impact factor: 5.923

4.  Distinctive sphingolipid patterns in chronic multiple sclerosis lesions.

Authors:  Maria Podbielska; Zdzislaw M Szulc; Toshio Ariga; Anna Pokryszko-Dragan; Wojciech Fortuna; Małgorzata Bilinska; Ryszard Podemski; Ewa Jaskiewicz; Ewa Kurowska; Robert K Yu; Edward L Hogan
Journal:  J Lipid Res       Date:  2020-08-07       Impact factor: 5.922

5.  Plasma lipidomics of monozygotic twins discordant for multiple sclerosis.

Authors:  Horst Penkert; Chris Lauber; Mathias J Gerl; Christian Klose; Markus Damm; Dirk Fitzner; Andrea Flierl-Hecht; Tania Kümpfel; Martin Kerschensteiner; Reinhard Hohlfeld; Lisa A Gerdes; Mikael Simons
Journal:  Ann Clin Transl Neurol       Date:  2020-11-07       Impact factor: 5.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.